Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis

Noazin, Sassan; Khamesipour, Ali; Moulton, Lawrence H.; Tanner, Marcel; Nasseri, Kiumarss; Modabber, Farrokh; Sharifi, Iraj; Khalil, E. A. G.; Bernal, Iván Darío Vélez; Antunes, Carlos; Smith, P. G.

doi:10.1016/j.vaccine.2009.05.084

Cited by 111 publications

(74 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These parasites provided poor antigens and thus did not trigger a robust immune response, even in the presence of adjuvants (summarized in the study by Noazin et al 20 ). The main advantages of using whole-killed parasite vaccines are their safety and easiness in mass production.…”

Section: Whole-killed Vaccinesmentioning

confidence: 99%

Cutaneous Leishmaniasis: Update on Vaccine Development

Zufferey¹,

Whyte²

2017

HPD

View full text Add to dashboard Cite

ABSTRACT:Leishmaniasis is an important disease mediated by the protozoan parasite Leishmania via the bite of the female sandfly insect vector. Leishmaniasis is endemic in the tropical and subtropical regions. The most common form of the disease is cutaneous leishmaniasis, which affects more than 10 million people worldwide and includes at least 1.5 million new cases every year. So far, treatment of the disease relies on unsatisfactory chemotherapy that can be complicated by the rising appearance of drug-resistant parasites. Furthermore, it is challenging to achieve solid control of the insect vector and animal reservoir. Therefore, the development of a safe and effective vaccine is urgently needed for the treatment and prevention of leishmaniasis. This review focuses on the recent advances in the development of a safe vaccine that could be used for prevention and treatment of cutaneous leishmaniasis. A short outlook for future research efforts is also presented.

show abstract

Section: Whole-killed Vaccinesmentioning

confidence: 99%

Cutaneous Leishmaniasis: Update on Vaccine Development

Zufferey¹,

Whyte²

2017

HPD

View full text Add to dashboard Cite

show abstract

“…While 1 st generation whole cell vaccines have largely failed 59 to show efficacy it is believed that subunit vaccines based on selected protein antigens can be developed 60 Immunogenic proteins of L. infantum promastigotes of mid-logarithmic growth phase were investigated by Dea-Ayuela and colleagues 64 . To guide identification, 72 randomly chosen landmark protein spots were analysed by mass spectrometry of which 29 could be identified.…”

Section: Identifying Immunogenic Proteinsmentioning

confidence: 99%

Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development

Paape

Aebischer

2011

Journal of Proteomics

View full text Add to dashboard Cite

:Leishmania spp., protozoan parasites with a digenetic life cycle, cause a spectrum of diseases in humans. Recently several Leishmania spp. have been sequenced which significantly boosted the number and quality of proteomic studies conducted. Here a historic review will summarize work of the pre-genomic era and then focus on studies after genome information became available. Firstly works comparing the different life cycle stages, in order to identify stage specific proteins, will be discussed. Identifying of post-translational modifications by proteomics especially phosphorylation events will be discussed. Further the contribution of proteomics to the understanding of the molecular mechanism of drug resistance and the investigation of immunogenic proteins for the identification of vaccine candidates will be summarized. Approaches of how potentially secreted proteins were identified are discussed. So far 30 -35% of the total predicted proteome of Leishmania spp. has been identified. This comprises mainly the abundant proteins, therefore the last section will look into technological approaches how this coverage may be increased and what the gel-free and gel-based proteomics have to offer will be compared.

show abstract

“…A relatively high agreement between the proteomic datasets that were generated from L. donovani 20 and L. mexicana 21,22 further suggests that for many if not most of these proteins their relative abundance will trials. 10 The experience with these vaccines highlights a critical issue in the comparatively resource poor programs of vaccine development against this disease: Low predictive power of available pre-clinical models and very slow and costly progress of prophylactic clinical vaccine testing programs. In recognition of these hurdles, improvements and alternative testing strategies have recently been proposed.…”

Section: From Genomes To Vaccinesmentioning

confidence: 99%